Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

被引：0
|
作者：
Nielsen, Katrine Finderup [1 ,4 ]
Nielsen, Lise Birk [1 ]
Dalby, Tine [1 ]
Lomholt, Frederikke Kristensen [1 ]
Slotved, Hans-Christian [1 ]
Fuursted, Kurt [1 ]
Harboe, Zitta Barrella [1 ,2 ,3 ]
Jorgensen, Charlotte Svaerke [1 ]
Valentiner-Branth, Palle [1 ]
机构：
[1] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen, Denmark
来源：
EMERGING INFECTIOUS DISEASES | 2024年 / 30卷 / 06期
关键词：
AGED; 65; ENGLAND; PNEUMONIA; PEOPLE; ADULTS; IMPACT; OLDER;
D O I：
10.3201/eid3006.230975
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >= 65 years of age as part of a vaccination program in Denmark during Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
引用
收藏
页码：1164 / 1172
页数：9
相关论文
共 50 条
  • [1] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, A
    O'Brien, K
    Watt, J
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1148 - 1148
  • [2] Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, AL
    O'Brien, KL
    Watt, JP
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01): : 81 - 89
  • [3] Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
    Andrews, Nick J.
    Waight, Pauline A.
    George, Robert C.
    Slack, Mary P. E.
    Miller, Elizabeth
    VACCINE, 2012, 30 (48) : 6802 - 6808
  • [4] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Vila-Corcoles, Angel
    Ochoa-Gondar, Olga
    Guzman, Jorge A.
    Rodriguez-Blanco, Teresa
    Salsench, Elisabet
    Fuentes, Cruz M.
    BMC INFECTIOUS DISEASES, 2010, 10
  • [5] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Angel Vila-Corcoles
    Olga Ochoa-Gondar
    Jorge A Guzmán
    Teresa Rodriguez-Blanco
    Elisabet Salsench
    Cruz M Fuentes
    BMC Infectious Diseases, 10
  • [6] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
    Tanimoto, Tetsuya
    Kusumi, Eiji
    Hosoda, Kazutaka
    Hamaki, Tamae
    Takahashi, Kenzo
    LANCET INFECTIOUS DISEASES, 2017, 17 (07): : 692 - 693
  • [7] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
    Suzuki, Motoi
    Dhoubhadel, Bhim Gopal
    Katoh, Shungo
    Ariyoshi, Koya
    Morimoto, Konosuke
    LANCET INFECTIOUS DISEASES, 2017, 17 (08): : 803 - 804
  • [8] Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017
    Shimbashi, Reiko
    Suzuki, Motoi
    Chang, Bin
    Watanabe, Hiroshi
    Tanabe, Yoshinari
    Kuronuma, Koji
    Oshima, Kengo
    Maruyama, Takaya
    Takeda, Hiroaki
    Kasahara, Kei
    Fujita, Jiro
    Nishi, Junichiro
    Kubota, Tetsuya
    Tanaka-Taya, Keiko
    Matsui, Tamano
    Sunagawa, Tomimasa
    Oishi, Kazunori
    EMERGING INFECTIOUS DISEASES, 2020, 26 (10) : 2378 - 2386
  • [9] Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska Native adults
    Singleton, Rosalyn J.
    Butler, Jay C.
    Bulkow, Lisa R.
    Hurlburt, Debby
    O'Brien, Katherine L.
    Doan, William
    Parkinson, Alan J.
    Hennessy, Thomas W.
    VACCINE, 2007, 25 (12) : 2288 - 2295
  • [10] Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study
    Suzuki, Motoi
    Dhoubhadel, Bhim Gopal
    Ishifuji, Tomoko
    Yasunami, Michio
    Yaegashi, Makito
    Asoh, Norichika
    Ishida, Masayuki
    Hamaguchi, Sugihiro
    Aoshima, Masahiro
    Ariyoshi, Koya
    Morimoto, Konosuke
    LANCET INFECTIOUS DISEASES, 2017, 17 (03): : 313 - 321
12345